A 61-year-old man with type 2 diabetes and hypertension has an eGFR of 65 mL/min/1.73 m² and an albumin-to-creatinine ratio (ACR) of 6 mg/mmol on two occasions. What is the most appropriate pharmacological intervention to reduce his risk of progression of kidney disease and cardiovascular events?